Results 161 to 170 of about 215,802 (313)

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Head &Neck, EarlyView.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor, Manasa Narasimman, Travis Vandergriff, Amy L. Jones   +3 more
wiley   +1 more source

Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and Predict Poor Clinical Outcome. [PDF]

Biomedicines, 2023
Soltan MA, Alhanshani AA, Shati AA, Alqahtani YA, Alshaya DS, Alharthi J, Altalhi SA, Fayad E, Zaki MSA, Eid RA.   +9 more
europepmc   +1 more source

Expression and significance of cyclin D1, cyclin-dependent kinase 4 and cyclin-dependent kinase inhibitor P27 in patients with non-neoplastic epithelial disorders of the vulva. [PDF]

Exp Ther Med, 2023
Liu H, Zhang F, Li Z.
europepmc   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Cyclin-dependent kinase inhibitor-1 deficiency enhances bone destruction in a mouse model of arthritis. [PDF]

Bone Rep
Wada K, Hayashi S, Onoi Y, Tachibana S, Suda Y, Saito A, Maeda T, Araki S, Motono K, Kamenaga T, Tsubosaka M, Kuroda Y, Nakano N, Matsumoto T, Kuroda R.   +14 more
europepmc   +1 more source

Editor's Note on 'PCAF regulates the stability of the transcriptional regulator and cyclin-dependent kinase inhibitor p27Kip1'. [PDF]

Nucleic Acids Res, 2023
europepmc   +1 more source

Deregulation of the cyclin-dependent kinase inhibitor p27 as a putative candidate for transformation in Chlamydia trachomatis infected mesenchymal stem cells. [PDF]

AIMS Microbiol, 2023
Abu-Lubad MA, Al-Zereini W, Al-Zeer MA.
europepmc   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Impact of Cyclin-dependent Kinase Inhibitor 1A Genotypes on Prostate Cancer Susceptibility Prediction. [PDF]

In Vivo
Liao CH, Bau DT, Wang BR, Chang SY, Hsia TC, Lee HT, Chen JC, Huang WC, Tsai CW, Wang YC, Shih HY, Chang WS.   +11 more
europepmc   +1 more source

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies [PDF]

, 2017
et al,, Govindan, Ramaswamy
core   +2 more sources